Kiora Pharmaceuticals, Inc. (KPRX)
Largest Insider Buys in Sector
KPRX Stock Price History Chart
KPRX Stock Performance
About Kiora Pharmaceuticals, Inc.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Insider Activity of Kiora Pharmaceuticals, Inc.
Over the last 12 months, insiders at Kiora Pharmaceuticals, Inc. have bought $48,761 and sold $0 worth of Kiora Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Kiora Pharmaceuticals, Inc. have bought $2.53M and sold $7.63M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Parsons Erin (director) — $25,669. Strem Brian M. (President and CEO) — $14,997. Daniels Eric Joseph (Chief Development Officer) — $7,570.
The last purchase of 1,431 shares for transaction amount of $7,570 was made by Daniels Eric Joseph (Chief Development Officer) on 2024‑06‑14.
List of Insider Buy and Sell Transactions, Kiora Pharmaceuticals, Inc.
| 2024-06-14 | Daniels Eric Joseph | Chief Development Officer | 1,431 0.0556% | $5.29 | $7,570 | -23.04% | ||
| 2024-06-14 | Tosca Melissa | EVP Finance | 100 0.0039% | $5.25 | $525 | -23.04% | ||
| 2024-06-13 | Strem Brian M. | President and CEO | 3,000 0.1101% | $5.00 | $14,997 | -13.84% | ||
| 2024-06-13 | Parsons Erin | director | 5,260 0.1885% | $4.88 | $25,669 | -13.84% | ||
| 2021-11-18 | Strem Brian M. | President and CEO | 17,853 0.1764% | $1.41 | $25,173 | -68.88% | ||
| 2021-08-02 | Sale | ARMISTICE CAPITAL, LLC | 10 percent owner | 192,775 1.8717% | $2.40 | $463,046 | -69.80% | |
| 2021-07-30 | Sale | ARMISTICE CAPITAL, LLC | 10 percent owner | 68,188 0.7096% | $2.69 | $183,562 | -70.83% | |
| 2021-07-29 | Sale | ARMISTICE CAPITAL, LLC | 400,000 4.0311% | $3.00 | $1.2M | -74.57% | ||
| 2021-07-28 | Sale | ARMISTICE CAPITAL, LLC | 375,443 3.7408% | $3.28 | $1.23M | -76.79% | ||
| 2021-07-27 | Sale | ARMISTICE CAPITAL, LLC | 2.38M 31.3018% | $5.09 | $12.11M | -79.90% | ||
| 2021-01-06 | ARMISTICE CAPITAL, LLC | 1.53M 21.542% | $5.22 | $8M | -32.02% | |||
| 2020-02-10 | ARMISTICE CAPITAL, LLC | 12,000 0.2683% | $6.04 | $72,480 | -18.43% | |||
| 2020-02-06 | ARMISTICE CAPITAL, LLC | 11,000 0.2463% | $6.18 | $67,980 | -20.16% | |||
| 2019-12-06 | Sale | GOLDBERG MORTON | director | 1,961 0.0619% | $6.93 | $13,590 | -27.54% | |
| 2019-11-12 | Sale | GOLDBERG MORTON | director | 2,001 0.06% | $4.29 | $8,584 | +12.00% | |
| 2019-09-30 | ARMISTICE CAPITAL, LLC | 5,001 0.1539% | $3.12 | $15,613 | +57.99% | |||
| 2019-09-29 | ARMISTICE CAPITAL, LLC | 600,000 19.9543% | $3.13 | $1.88M | +57.99% | |||
| 2019-07-15 | Sale | FROM STEPHEN | President and CEO | 42,452 0.0913% | $0.23 | $9,891 | +38.68% | |
| 2019-07-15 | Sale | Wirostko Barbara | Chief Medical Officer | 6,488 0.014% | $0.23 | $1,512 | +38.68% | |
| 2019-07-15 | Sale | Romano Sarah | Chief Financial Officer | 6,584 0.0142% | $0.23 | $1,534 | +38.68% |
Insider Historical Profitability
| Daniels Eric Joseph | Chief Development Officer | 11222 0.3907% | $4.00 | 1 | 0 | |
| Strem Brian M. | President and CEO | 14531 0.356% | $4.00 | 2 | 0 | <0.0001% |
| Parsons Erin | director | 5260 0.1831% | $4.00 | 1 | 0 | |
| Tosca Melissa | EVP Finance | 3979 0.1385% | $4.00 | 1 | 0 | |
| IPSA (INNOVEN PARTENAIRES S.A.) | 10 percent owner | 1460479 18.9938% | $4.00 | 1 | 0 | |
| Ventech Capital II | 10 percent owner | 1431814 18.621% | $4.00 | 1 | 6 | |
| FROM STEPHEN | President and CEO | 1032465 13.4274% | $4.00 | 4 | 3 | |
| ARMISTICE CAPITAL, LLC | 10 percent owner | 785000 10.2091% | $4.00 | 31 | 5 | |
| Wirostko Barbara | Chief Medical Officer | 405534 5.274% | $4.00 | 0 | 3 | |
| Romano Sarah | Chief Financial Officer | 262113 3.4088% | $4.00 | 3 | 3 | |
| MANZO MICHAEL P. | VP of Engineering | 174796 2.2733% | $4.00 | 0 | 3 | |
| Mann Brenda | VP of Research & Development | 174424 2.2684% | $4.00 | 0 | 3 | |
| Garanzini Michael | Chief Commercial Officer | 171250 2.2271% | $4.00 | 1 | 0 | |
| CHANEY PAUL G | director | 8333 0.1084% | $4.00 | 1 | 0 | |
| GOLDBERG MORTON | director | 0 0% | $4.00 | 0 | 7 |
Institutional Investor Ownership
No records found… | |||||||